FIELD: medicine.
SUBSTANCE: invention represents a method for identifying the factors of genetic predisposition to breast cancer involving genetic marker recording by a massive parallel sequencing followed by sampling and analyzing in depth injurious mutations only among the patients suffering breast cancer; a differential characteristic of the method is that identifying the recessive factors of the genetic predisposition to breast cancer enables involving the patients with a medical history having an early age of the onset, primary multiple cancer and no cases of breast cancer or ovarian cancer in the family; the analysis procedure covers only the mutations found in the homozygous state.
EFFECT: expanding the methods for identifying the genetic predisposition to breast cancer.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR MOLECULAR-GENETIC DIAGNOSIS OF HEREDITARY BREAST CANCER | 2019 |
|
RU2702755C1 |
| METHOD FOR PREDICTION OF GENETIC PREDISPOSITION TO BREAST CANCER | 2012 |
|
RU2522501C1 |
| METHOD OF PREDICTING A LOW RISK OF DEVELOPING BREAST CANCER IN WOMEN WITH HIGHLY PENETRATING MUTATIONS IN THE BRCA1 AND CHEK2 GENES | 2022 |
|
RU2798666C1 |
| DETERMINATION OF CANCER SUSCEPTIBILITY BY IDENTIFICATION OF GENOTYPIC COMBINATIONS OF SPECIFIC VERSIONS OF CYP1B1, BRCA2 AND CHEK2 GENES | 2006 |
|
RU2470998C2 |
| METHOD FOR PREDICTION OF RISK OF MALIGNANT DISEASES OF MAMMARY GLAND AND/OR OVARIES IN PATIENTS AFTER KIDNEY TRANSPLANTATION | 2023 |
|
RU2821583C1 |
| METHOD OF DIFFERENTIATED USE OF DNA SEQUENCING DATA FOR PATIENTS AFTER KIDNEY TRANSPLANTATION | 2022 |
|
RU2803796C1 |
| SET OF SYNTHETIC OLIGONUCLEOTIDES FOR DETERMINATION OF NUCLEOTIDE SEQUENCE OF CODING PART OF BRCA1 GENE AND DETECTION OF MUTATIONS, ASSOCIATED WITH HEREDITARY FORMS OF BREAST CANCER | 2010 |
|
RU2440415C1 |
| METHOD OF PREDICTING THE RISK OF OVARIAN CANCER | 2015 |
|
RU2599502C1 |
| METHOD FOR DETECTION OF RISK OF HEREDITAL DETERMINATION OF BREAST CANCER BASED ON ANAMNETIC DATA | 2016 |
|
RU2628865C1 |
| METHOD FOR DETERMINING GENETIC MARKERS FOR ASSESSING POLYGENIC RISK OF BREAST CANCER (HORMONE-NEGATIVE AND HORMONE-POSITIVE SUBTYPES) | 2020 |
|
RU2749465C1 |
